Skip to content

A Study on Unani regimen for prevention of high/moderate risk population of COVID 19

A Study on prophylactic interventions of Unani Medicine on high/moderate risk population of COVID 19

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/026227
Enrollment
60
Registered
2020-06-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Khameera Marwareed: 5g orally once daily in the morning for 14days Intervention2: Tiryaq-e-Arba: 5gm orally with lukewarm water in the Morning for 14days Intervention3: Unani Joshanda/d

Sponsors

Central Council for Research in Unani Medicine CCRUM New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Population as described as High/ Moderate Risk group 2.Individuals who are from the identified quarantine facility 3.Subjects who are ready to provide written/digital informed consent and who are willing to participate and follow the protocol requirements of the clinical study

Exclusion criteria

Exclusion criteria: 1.Persons with severe primary respiratory disease or related complications that may be identified with COVID-19 2.Laboratory confirmed COVID-19 with or without symptoms 3.Pregnant and lactating mothers and those who have a pregnancy plan. 4.Persons with serious critical illness, or severe mental illnesses 5.Individuals with clinical history of uncontrolled/ unstable co-morbidities 6.Known Immuno-compromised individuals or those on immune-suppressantdrugs and steroids 7.Subjects having a past history of allergy to any medicine that is a part of the Unani intervention.

Design outcomes

Primary

MeasureTime frame
Incidence of COVID-19 cases in control as well in interventional group Timepoint: 14 days

Secondary

MeasureTime frame
Improvement in immune status using Immune Status Questionnaire (ISQ)Timepoint: 14 days

Countries

India

Contacts

Public ContactDr Pradeep Kumar

CCRUM

ccrum507@rediffmail.com9213511298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026